BriaCell Provides Update on Remarkable Responder
13 January 2020 - 10:30PM
BriaCell Therapeutics Corp. ("BriaCell" or the "Company")
(TSX-V:BCT) (OTCQB:BCTXD), a clinical-stage biotechnology
company specializing in targeted immunotherapy for advanced breast
cancer, is pleased to provide an update on the previously-announced
(Link) top responder (“Remarkable Responder”) in the combination
study of its lead candidate, Bria-IMT™, with Incyte’s INCMGA00012,
a PD-1 inhibitor.
The patient, who had experienced notable tumor
shrinkage while on treatment with Bria-IMT™ in combination with the
PD-1 inhibitor pembrolizumab [KEYTRUDA®; manufactured by Merck
& Co., Inc. (NYSE: MRK)], has since transitioned to treatment
in combination with INCMGA00012. On this combination
treatment, the patient has had a subsequent further remarkable
reduction in a breast cancer tumor behind the left eye in the left
orbital region. This tumor, which had pushed the eye forward from
the skull (known as proptosis), has resolved following 3 months of
treatment. The tumor had shrunk by 19% during treatment with
the Bria-IMT™ regimen in combination with KEYTRUDA®, and has now
completely disappeared during treatment in combination
INCMGA00012. While not all of the patient’s tumors have
resolved, the proptosis and associated eye problem have been
resolved.
BriaCell’s “matching hypothesis” has been
further strengthened: The Remarkable Responder matched Bria-IMT™ at
2 HLA loci (HLA-C and HLA-DRB3). BriaCell’s immunotherapy treatment
appears most effective when the patient’s HLA-type matches the
Bria-IMT™ HLA-type as concluded in prior Phase IIa proof-of-concept
work.
“The complete regression of a tumor this large
and this advanced, in a patient resistant to 16 previous treatment
regimens, is unprecedented in my 50 years of clinical practice,”
said Dr. Charles Wiseman, BriaCell’s Scientific Founder and
Director. “These very important positive clinical observations
support BriaCell’s strategy to continue investigating the
combination regimen of Bria-IMT™ with checkpoint inhibitors, and
may lead to a new treatment option for breast cancer patients
suffering advanced, resistant disease.”
About
BriaCell
BriaCell is an immuno-oncology focused
biotechnology company developing targeted and safe approaches for
the management of cancer.
BriaCell is conducting a Phase I/IIa clinical
trial of Bria-IMT™, BriaCell’s lead candidate, in a Combination
Study with immune checkpoint inhibitors such as the Incyte drugs
INCMGA00012 (an anti-PD-1 antibody similar to pembrolizumab
[KEYTRUDA®; manufactured by Merck & Co., Inc. (NYSE: MRK)]) and
epacadostat, an orally bioavailable small-molecule inhibitor of
indoleamine 2,3-dioxygenase 1 (IDO1). The combination study is
listed in ClinicalTrials.gov as NCT03328026.
BriaCell currently has a non-exclusive clinical
trial collaboration with Incyte Corporation to evaluate the effects
of combinations of novel clinical candidates. Under the agreement,
Incyte and BriaCell will be evaluating novel combinations of
compounds from Incyte’s development portfolio with BriaCell’s drug
candidates in advanced breast cancer patients.
BriaCell is also developing Bria-OTS™, an
off-the-shelf personalized immunotherapy, for advanced breast
cancer. Bria-OTS™ immunotherapy treatments are personalized to
match the patient without the need for personalized manufacturing.
Bria-OTS™, which is expected to cover over 99 percent of the
patient population, is designed to produce a potent and selective
immune response against the cancer of each patient while
eliminating the time, expense and complex manufacturing logistics
associated with other personalized immunotherapies.
For additional information on BriaCell, please
visit: https://briacell.com/.
Cautionary Note Regarding Forward-Looking
Information
Except for the statements of historical fact,
this news release contains "forward-looking information" within the
meaning of the applicable Canadian securities legislation which
involves known and unknown risks relevant to the Company in
particular and to the biotechnology and pharmaceutical industries
in general, uncertainties and other factors that may cause actual
events to differ materially from current expectation. These risks
are more fully described in the Company's public filings available
at www.sedar.com.
Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date of this press release. The Company disclaims any
intention or obligation, except to the extent required by law, to
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Contact Information
For further information, please
contact:BriaCell Therapeutics Corp.:Farrah
DeanManager, Corporate DevelopmentEmail: farrah@BriaCell.com Phone:
1-888-485-6340
BriaCell Therapeutics (TSXV:BCT)
Historical Stock Chart
From Apr 2024 to May 2024
BriaCell Therapeutics (TSXV:BCT)
Historical Stock Chart
From May 2023 to May 2024